News tagged with bevacizumab
CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness
Researchers at Virginia Commonwealth University Medical Center's VCU Massey Cancer Center and Harold F. Young Neurosurgical Center (Richmond, VA) and Old Dominion University (Norfolk, VA) have discovered that suppression ...
Medicine & Health / Neuroscience
Feb 07, 2012 |
not rated yet |
0
Avastin, Sutent increase breast cancer stem cells, study shows
Cancer treatments designed to block the growth of blood vessels were found to increase the number of cancer stem cells in breast tumors in mice, suggesting a possible explanation for why these drugs don't ...
Jan 25, 2012 |
5 / 5 (1) |
1
|
Targeted therapy extends progression-free survival of patients with advanced ovarian cancer
Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic ...
Dec 28, 2011 |
not rated yet |
0
|
Spread of nasopharyngeal carcinoma is reduced by bevacizumab, according to phase 2 trial results
The trial conducted by the Radiation Therapy Oncology Group (RTOG) shows the feasibility to deliver bevacizumab to the current chemoradiation standard without any apparent increased adverse side effects.
Dec 16, 2011 |
not rated yet |
0
Addition of bevacizumab to conventional therapy improved progression-free survival in HER2-positive breast cancer
Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from ...
Dec 08, 2011 |
not rated yet |
0
Scientists find link between immune system suppression, blood vessel formation in tumors
Targeted therapies that are designed to suppress the formation of new blood vessels in tumors, such as Avastin (bevacizumab), have slowed cancer growth in some patients. However, they have not produced the dramatic responses ...
Jul 13, 2011 |
not rated yet |
0
|
Ovarian cancer outcomes may improve with 'dose-dense' chemotherapy
Dose-dense chemotherapy has shown promise in smaller clinical trials, and now is being investigated in a multi-center, phase III study in which nearly 700 women will participate. Earlier phase II trials pointed to anti-cancer ...
Jun 30, 2011 |
not rated yet |
0
US panel rejects Avastin for breast cancer use
An expert panel urged the US Food and Drug Administration on Wednesday to strip the Roche-made drug Avastin of its label for use against breast cancer because it is neither safe nor effective.
Medicine & Health / Medications
Jun 29, 2011 |
not rated yet |
0
FDA panel: Revoke drug's breast cancer approval
(AP) -- A panel of cancer experts has ruled for a second time that Avastin, the best-selling cancer drug in the world, should no longer be used in breast cancer patients, clearing the way for the government to remove its ...
Medicine & Health / Medications
Jun 28, 2011 |
not rated yet |
0
Blood proteins may identify vulnerability of pancreatic cancers to avastin
(Medical Xpress) -- Tiny tumor proteins circulating in blood may be used to identify which pancreatic cancer patients would benefit from the drug Avastin, researchers at Duke University Medical Center have found.
Jun 07, 2011 |
not rated yet |
0
New drug combination slows tumor growth for recurrent ovarian cancer
Bevacizumab (Avastin) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by ...
Jun 06, 2011 |
not rated yet |
0
Antifungal drug delays need for chemo in advanced prostate cancer
The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease. Details of the finding, from a clinical ...
Jun 02, 2011 |
not rated yet |
0
Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients
The standard treatment for patients with advanced non-small cell lung cancer (NSCLC) is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now, Fox ...
Jun 01, 2011 |
not rated yet |
0
GOLFIG increased progression-free survival in colorectal cancer patients
Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival, according to Phase III study results presented at the AACR 102nd Annual Meeting ...
Apr 06, 2011 |
not rated yet |
0
Targeted ovarian cancer therapy not cost-effective: study
An analysis conducted by Ohio State University cancer researchers has found that adding the targeted therapy bevacizumab to the treatment of patients with advanced ovarian cancer is not cost effective.
Mar 07, 2011 |
not rated yet |
0
Bevacizumab
Bevacizumab (trade name Avastin, Genentech/Roche) is a drug that blocks angiogenesis, the growth of new blood vessels. It is commonly used to treat various cancers, including colorectal, lung, breast, kidney, and glioblastomas.
Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.[citation needed]
Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) for certain metastatic cancers. It received its first approval in 2004 for combination use with standard chemotherapy for metastatic colon cancer. While at one point approved for breast cancer by the FDA, the approval was revoked on 18 November 2011.
The approval for breast cancer was controversial, because although there was evidence that it slowed progression of metastatic breast cancer, there was no evidence that it extended life, or improved quality of life, and it caused adverse effects including severe high blood pressure and hemorrhaging. In 2008, the FDA gave bevacizumab provisional approval for metastatic breast cancer, subject to further studies. The FDA's advisory panel had recommended against approval. In July 2010, after new studies, the FDA's advisory panel again recommended against the indication for advanced breast cancer. Genentech requested a hearing, which was granted in June 2011. The FDA finally ruled to withdraw the breast cancer indication in November 2011. FDA approval is only required for Genentech to market a drug for that indication. Doctors can still prescribe it for that indication, although insurance companies are less likely to pay for it.
The drug is still approved for use in Australia.
In the curative setting (adjuvant therapy), clinical studies are still underway in breast cancer and lung cancer. A study released in April 2009 found that bevacizumab is not effective at preventing recurrences of non-metastatic colon cancer following surgery. In May 2009, it received FDA approval for treatment of recurring glioblastoma multiforme, while treatment for initial growth is still in phase III clinical trial.
For more information about Bevacizumab, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.